Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) monotherapy has shown promising results thus far, although development of resistance is a clinical challenge. The objective of this study was to cha...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Hanly, Elyse K., Tuli, Neha Y., Bednarczyk, Robert B., Suriano, Robert, Geliebter, Jan, Moscatello, Augustine L., Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2015
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4890996/
https://ncbi.nlm.nih.gov/pubmed/26735176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6779
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker